N-Acetyl Epitalon
N-Acetyl Epithalon, Ac-AEDG, N-acetyl-Ala-Glu-Asp-Gly, N-Acetyl Epitalon Amidate
N-Acetyl Epitalon is a chemically modified version of Epitalon in which the N-terminus carries an acetyl group, marketed on the claim that this improves stability and absorption. There is no published research on this specific molecule at all. PubMed searches return zero records under any spelling.
Mechanism
No mechanism has been demonstrated for this analogue, because no study of it has been published. The rationale offered by sellers is generic peptide chemistry rather than anything measured: N-terminal acetylation removes the free alpha-amino group, which blocks degradation by aminopeptidases and typically extends plasma survival of a short peptide; it also lowers net positive charge and slightly increases lipophilicity, which can affect membrane permeability. Some vendor products additionally amidate the C-terminus, blocking carboxypeptidases as well, and the naming is used inconsistently across sellers, so two products labelled 'N-acetyl epitalon' are not necessarily the same compound.
Whichever variant is meant, the proposed downstream mechanism is simply inherited from Epitalon: nuclear entry and interaction with promoter DNA, with claimed induction of hTERT. Because acetylation changes the charge and hydrogen-bonding pattern at exactly the terminus that would participate in any such DNA contact, it cannot be assumed that activity carries over from the parent peptide. There is a second reason for doubt: modelling work from the originating group proposes that ultrashort peptides of this family enter cells through the LAT and PEPT amino acid and peptide transporters, and those transporters are generally sensitive to the charge state of the substrate's N-terminus. Acetylation would be expected to affect that recognition. Neither concern has ever been tested experimentally.
What the research shows
There is nothing to report. Searches of PubMed for 'N-acetyl epitalon', 'acetyl-epitalon' and 'N-acetyl-epithalon' return zero indexed records, re-run and confirmed during this audit. There are no cell-culture studies, no animal studies, no pharmacokinetic characterisation, no toxicology, and no clinical trials. There is not even the preclinical foundation that exists for the parent compound.
This makes N-Acetyl Epitalon a clean illustration of a pattern that recurs across the online peptide market: a modification is applied to a compound that itself has thin evidence, the modification is given a plausible-sounding chemical justification, and the resulting product is then marketed as an upgrade. The claimed advantages, better stability, better oral or intranasal bioavailability, longer duration of action, are hypotheses drawn from general peptide chemistry. None has been measured for this molecule. Any statement about how it performs relative to Epitalon in a living organism is, at present, invention.
Evidence assessment
Preclinical only
Tier assigned only because the schema has no lower category; in fact there is no published evidence of any kind, preclinical or otherwise, for this specific analogue.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells Preclinical only
The parent unmodified peptide induced telomerase catalytic subunit expression, telomerase activity and telomere elongation in culture.
Safety
Completely uncharacterised. There is no toxicology, no animal safety data and no human exposure record. The absence of reported harms reflects the absence of any study, not a demonstrated safety margin. Compounding the problem, because no reference standard or published analytical method exists, buyers cannot verify that a vial labelled N-acetyl epitalon contains the acetylated peptide rather than unmodified Epitalon, a mixture, or something else.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. As with the parent compound, supply for human use would engage the Human Medicines Regulations 2012 irrespective of a 'research use only' label. |
| United States | No FDA approval, no investigational status, no registered trial. Sold only through research-chemical channels. It has never been reviewed by any regulator in any jurisdiction. |
| WADA (sport) | Not individually named on the WADA Prohibited List, but captured by section S0 (non-approved substances), which prohibits at all times any pharmacological substance not approved by any government health authority for human therapeutic use. A novel unapproved analogue falls squarely within that category. |
Questions
Nobody knows. No study has compared them, and no pharmacokinetic data exist for the acetylated form in any species. The claim rests on the general principle that N-terminal acetylation slows aminopeptidase degradation, which has never been demonstrated for this molecule.
None. A PubMed search under every common spelling returns zero records. There is no cell study, no animal study, no toxicology and no clinical trial.
A vendor designation implying the peptide is acetylated at the N-terminus and amidated at the C-terminus. Naming is inconsistent between sellers, so products under this label are not necessarily the same molecule, and no analytical standard has been published to check.
Unknown, which is not the same as safe. There is no toxicology in any species and no human exposure record. Purity and identity of material sold online are also unverifiable.